| pubmed-article:2155728 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C0010823 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C0877837 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C0007634 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C0037993 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C1302234 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C0439662 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:2155728 | lifeskim:mentions | umls-concept:C0076577 | lld:lifeskim |
| pubmed-article:2155728 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:2155728 | pubmed:dateCreated | 1990-4-23 | lld:pubmed |
| pubmed-article:2155728 | pubmed:abstractText | Infection of mice with murine cytomegalovirus (CMV) presents a model for the study of the role of the immune system in the pathogenesis of human CMV. We performed adoptive transfer experiments to evaluate the prospects for enhancing the anti-viral potential of murine CMV immune spleen cells by THF-gamma 2. Adult BALB/c mice resistant to murine CMV become highly susceptible following immunosuppression by cyclophosphamide. Recipient mice were injected with murine CMV and cyclophosphamide concomitantly, and 24 h later adoptive transfers of syngeneic immune spleen cells were performed. We showed that passive transfers of murine CMV immune spleen cells prevented the development of a fatal disease in 38% of the recipient mice. Daily injections of murine CMV immune donor mice with THF-gamma 2 enhanced considerably (93%) the therapeutic potential of virus-specific immune cells. These experiments provide direct evidence for the antiviral capacity of THF-gamma 2 through its immunomodulatory effect on immune T cells. | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2155728 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2155728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2155728 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2155728 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:2155728 | pubmed:issn | 0009-9104 | lld:pubmed |
| pubmed-article:2155728 | pubmed:author | pubmed-author:TraininNN | lld:pubmed |
| pubmed-article:2155728 | pubmed:author | pubmed-author:BursteinYY | lld:pubmed |
| pubmed-article:2155728 | pubmed:author | pubmed-author:Rager-ZismanB... | lld:pubmed |
| pubmed-article:2155728 | pubmed:author | pubmed-author:PechtMM | lld:pubmed |
| pubmed-article:2155728 | pubmed:author | pubmed-author:BenharrochDD | lld:pubmed |
| pubmed-article:2155728 | pubmed:author | pubmed-author:ZuckermanFF | lld:pubmed |
| pubmed-article:2155728 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2155728 | pubmed:volume | 79 | lld:pubmed |
| pubmed-article:2155728 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2155728 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2155728 | pubmed:pagination | 246-52 | lld:pubmed |
| pubmed-article:2155728 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:meshHeading | pubmed-meshheading:2155728-... | lld:pubmed |
| pubmed-article:2155728 | pubmed:year | 1990 | lld:pubmed |
| pubmed-article:2155728 | pubmed:articleTitle | Therapy of a fatal murine cytomegalovirus infection with thymic humoral factor (THF-gamma 2) treated immune spleen cells. | lld:pubmed |
| pubmed-article:2155728 | pubmed:affiliation | Department of Microbiology and Immunology, Ben Gurion University of the Negev, Beer Sheva, Israel. | lld:pubmed |
| pubmed-article:2155728 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2155728 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:2155728 | lld:pubmed |
